Education
About Us
Working with TipRanks
Follow Us
Genomma Lab Internacional SAB de CV Class B (DE:GEKA)
FRANKFURT:GEKA
GEKA Stock Chart & Stats
€0.80
€0.04(3.33%)
At close: 4:00 PM EST
€0.80
€0.04(3.33%)
Day’s Range― - ―
52-Week Range€0.77 - €1.35
Previous CloseN/A
Volume0.00
Average Volume (3M)110.00
Market Cap
$826.88M
Enterprise Value€24.81B
Total Cash (Recent Filing)$2.38B
Total Debt (Recent Filing)$5.06B
Price to Earnings (P/E)9.7
Beta0.37
Next Earnings
Feb 25, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding1,000,000,000
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap30.01
Enterprise Value/Revenue2.42
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda10.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genomma Lab Internacional SAB de CV News
GEKA FAQ
What was Genomma Lab Internacional SAB de CV Class B’s price range in the past 12 months?
Genomma Lab Internacional SAB de CV Class B lowest stock price was €0.77 and its highest was €1.35 in the past 12 months.
What is Genomma Lab Internacional SAB de CV Class B’s market cap?
Genomma Lab Internacional SAB de CV Class B’s market cap is $826.88M.
When is Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date?
Genomma Lab Internacional SAB de CV Class B’s upcoming earnings report date is Feb 25, 2026 which is in 109 days.
How were Genomma Lab Internacional SAB de CV Class B’s earnings last quarter?
Genomma Lab Internacional SAB de CV Class B released its earnings results on Oct 23, 2025. The company reported €0.029 earnings per share for the quarter, beating the consensus estimate of €0.024 by €0.005.
Is Genomma Lab Internacional SAB de CV Class B overvalued?
According to Wall Street analysts Genomma Lab Internacional SAB de CV Class B’s price is currently Overvalued.
Does Genomma Lab Internacional SAB de CV Class B pay dividends?
Genomma Lab Internacional SAB de CV Class B does not currently pay dividends.
What is Genomma Lab Internacional SAB de CV Class B’s EPS estimate?
Genomma Lab Internacional SAB de CV Class B’s EPS estimate is 0.02.
How many shares outstanding does Genomma Lab Internacional SAB de CV Class B have?
Genomma Lab Internacional SAB de CV Class B has 1,000,000,000 shares outstanding.
What happened to Genomma Lab Internacional SAB de CV Class B’s price movement after its last earnings report?
Genomma Lab Internacional SAB de CV Class B reported an EPS of €0.029 in its last earnings report, beating expectations of €0.024. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Genomma Lab Internacional SAB de CV Class B?
Currently, no hedge funds are holding shares in DE:GEKA
Company Description
Genomma Lab Internacional SAB de CV Class B
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
GEKA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presents a company facing significant challenges, including a decline in sales due to external economic conditions and hyperinflationary effects. However, the management's focus on cost-saving measures and strategic investments in growth initiatives highlights a proactive approach to overcoming these hurdles. The resilience of the EBITDA margin and strong historical growth provide a foundation for potential recovery.View all DE:GEKA earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---